ANNX
Annexon, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.01
+17.60%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$3.65
From 52W high−42.39%
Volume6.23M
Market cap$760.21M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$3.65
From 52W high
−42.39%
Volume
6.23M
Market cap
$760.21M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.9x
P/E (TTM)
—
RSI (14)
42.4
MomentumView details →
1D Return
+17.60%
YTD Return
−24.50%
SummaryUpdated Jun 1, 2026
Annexon, Inc. (NASDAQ:ANNX) is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in Brisbane, California. The company went public in July 2020 and focuses on discovering and developing novel therapeutics that target the complement system, a critical component of the immune system. Annexon's approach centers on inhibiting C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic disorders where excessive complement activation contributes to disease progression.
Similar companies
Latest newsMore news →
Annexon granted inducement awards to six new non-executive employees under its 2022 Employment Inducement Award Plan.3d agoAnnexon, Inc. announced two oral presentations on vonaprument at The Retina Society 59th Annual Scientific Meeting in Los Angeles, presenting patient baseline characteristics from the Phase 3 ARCHER II pivotal trial for geographic atrophy.26d agoAnnexon granted equity inducement awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved on September 12, 2026, per Nasdaq Listing Rule 5635(c)(4).33d ago